APA (7th ed.) Citation

Metsemakers, S. J., Hermens, R. P., Ector, G. I., Blijlevens, N. M., & Govers, T. M. (2025). The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction. Value in Health, 28(2), 224. https://doi.org/10.1016/j.jval.2024.12.005

Chicago Style (17th ed.) Citation

Metsemakers, Sanne J.J.P.M., Rosella P.M.G Hermens, Geneviève I.C.G Ector, Nicole M.A Blijlevens, and Tim M. Govers. "The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction." Value in Health 28, no. 2 (2025): 224. https://doi.org/10.1016/j.jval.2024.12.005.

MLA (9th ed.) Citation

Metsemakers, Sanne J.J.P.M., et al. "The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction." Value in Health, vol. 28, no. 2, 2025, p. 224, https://doi.org/10.1016/j.jval.2024.12.005.